EMA Authorised: Rebif (interferon beta-1a) — Merck Europe B.V.

View source ↗

Summary

EMA has authorised Rebif (interferon beta-1a) for use in the treatment of multiple sclerosis, with Merck Europe B.V. listed as the marketing authorisation holde…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Merck Europe B.V.. Decision date: 13/02/2026